Search

Displaying results 4491 - 4500 of 8578 in total
  1. Drug

    Crotedumab

    go.drugbank.com/drugs/DB12815
    Investigational

    Crotedumab has been used in trials studying the treatment of Diabetes Mellitus, Type 2.

  2. Drug

    Tetrasul

    go.drugbank.com/drugs/DB12838
    Investigational

    Tetrasul has been used in trials studying the treatment of Erythematous (Type One) Rosacea.

  3. Drug

    Miravirsen

    go.drugbank.com/drugs/DB12851
    Investigational

    Miravirsen has been investigated for the treatment of Hepatitis C and Hepatitis C, Chronic.

  4. Drug

    Diethylhomospermine

    go.drugbank.com/drugs/DB13011
    Investigational

    Diethylhomospermine has been used in trials studying the treatment of Diarrhea and HIV Infections.

  5. Drug

    1-benzylimidazole

    go.drugbank.com/drugs/DB04581
    Experimental

    1-benzylimidazole, an N-imidazole derivative, has been shown to have strong cardiotonic activity.

  6. Drug

    Tulobuterol

    go.drugbank.com/drugs/DB12248
    Investigational

    Tulobuterol has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.

  7. Drug

    AVI-4065

    go.drugbank.com/drugs/DB05620
    Investigational

    It was developed by Sarepta Therapeutics, Inc. After phase II trials it was cancelled due to lack of potency. [L2917]

  8. Drug

    Talsupram

    go.drugbank.com/drugs/DB09191
    Experimental

    It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to [citalopram].

  9. Drug

    LC16M8

    go.drugbank.com/drugs/DB05019
    Investigational

    LC16m8 is a next-generation, attenuated smallpox vaccine that is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines. It is the only attenuated vaccine to be licensed for use in ...

  10. Drug

    Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15731
    Investigational

    Regarding the modifications of these UC-MSCs, CD362, also known as syndecan-2, is a surface marker identified on MSCs with enhanced clonogenicity and immunomodulatory properties.